Showing results (1-10 of 61) with videos related to
Sort By:
Pageof 7
Future Oncology (London, England)|November 3, 2011
Ipilimumab: showing survival benefit in metastatic melanomaAnna Minchom, Kate Young, James LarkinTherapeutic Advances in Medical Oncology|July 20, 2018
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategiesAnna Minchom, Caterina Aversa, Juanita LopezFuture Oncology (London, England)|June 1, 2012
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutationKate Young, Anna Minchom, James LarkinJournal of Gastrointestinal Cancer|January 14, 2010
An unusual case of pancreatic cancer with leptomeningeal infiltrationAnna Minchom, Samuel Chan, Walter Melia, et al.European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancerDaisy W S Mak, Su Li, Anna MinchomCNS Oncology|July 24, 2014
The diagnosis and treatment of brain metastases in EGFR mutant lung cancerAnna Minchom, Ken C Yu, Jaishree Bhosle, et al.Cancer Medicine|October 22, 2021
Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials.govJulia Lai-Kwon, Zhulin Yin, Anna Minchom, et al.Critical Reviews in Oncology/Hematology|January 22, 2021
Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspectiveJulia Lai-Kwon, Crescens Tiu, Abhijit Pal, et al.Eclinicalmedicine|October 2, 2023
Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological reviewEmily Alger, Anna Minchom, Olalekan Lee Aiyegbusi, et al.Psycho-Oncology|October 15, 2021
Assessing cognitive toxicity in early phase trials - What are we missing?Sarah E Stapleton, Anne-Sophie Darlington, Anna Minchom, et al.Pageof 7